Gadolinium contrast

Phase 2Small molecule

WWashington University School of Medicine

Gadolinium contrast is one of 69 small molecule programs targeting Brain Injury. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain InjuryActive, not recruiting

Neurofibromatosis Type 1Active, not recruiting

Brain InjuryPhase 2

Active, not recruiting

Neurofibromatosis Type 1Preclinical

Active, not recruiting

Competition

Competitive Landscape

245 competitors in Brain Injury

#DrugCompanyPhaseTrials

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 2

Brintellix

Takeda

Phase 3

1 3

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

5 4

Cyklokapron

AAmring

Phase 3

4 5

Nuvigil

NNuvo Research GmbH

Phase 3

2 6

Prometrium

Ferring

Phase 3

2 7

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

2 8

Rocephin

CConrado Roberto Hoffmann Filho

Phase 3

1 9

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

—10

Xe-133

NNobilis Therapeutics Inc.

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neurofibromatosis Type 11 trial

Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma

Terminated·WWashington University School of Medicine·N/A·NCT02584413·29 enrolled

Brain Injury1 trial

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

Terminated·UUniformed Services University of the Health Sciences·Phase 2·NCT04058132·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Gadolinium contrast. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gadolinium contrast compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gadolinium contrast. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWashington University School of Medicine

Gadolinium contrast

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neurofibromatosis Type 11 trial

Brain Injury1 trial

References

Drug Info

Quick Facts

Related News